Potential use of microRNA-200c as a prognostic marker in non-small cell lung cancer

Oncology Letters

Volumn 14, Issue 4, 2017, Pages 4325-4330

  Si, Libo ^a   Tian, Hui ^a   Yue, Weiming ^a   Li, Lin ^a   Li, Shuhai ^a   Gao, Cun ^a   Qi, Lei ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Disease free survival; MicroRNA 200c; Non small cell lung cancer; Overall survival; Prognosis

Indexed keywords

COMPLEMENTARY DNA; MICRORNA 200C; NUCLEIC ACID; TUMOR MARKER; UNTRANSLATED RNA;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; DISEASE FREE INTERVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 85028941895     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2017.6667     Document Type: Article

References (37)

1. Sibille A, Paulus A, Martin M, Bourhaba M, Barthélemy N, Radermecker M, Corhay JL, Louis R and Duysinx B: Management of non-small cell lung cancer. Rev Med Liege 70: 432-441, 2015 (In French).
2. Venkatesulu BP, Mallick S, Singh A and Julka PK: Non small cell carcinoma of lung with metachronous breast metastasis and cardiac tamponade: Unusual presentation of a common cancer. J Egypt Natl Canc Inst 27: 165-169, 2015.
3. Sun Z, Wang Z, Liu X and Wang D: New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. Anticancer Drugs 26: 1-14, 2015.
4. Wu CF, Fu JY, Yeh CJ, Liu YH, Hsieh MJ, Wu YC, Wu CY, Tsai YH and Chou WC: Recurrence risk factors analysis for stage I non-small cell lung cancer. Medicine (Baltimore) 94: e1337, 2015.
5. Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell 136: 215-233, 2009.
6. Feng B, Zhang K, Wang R and Chen L: Non-small-cell lung cancer and miRNAs: Novel biomarkers and promising tools for treatment. Clin Sci (Lond) 128: 619-634, 2015.
7. Ghasemkhani N, Shadvar S, Masoudi Y, Talaei AJ, Yahaghi E, Goudarzi PK and Shakiba E: Down-regulated MicroRNA 148b expression as predictive biomarker and its prognostic significance associated with clinicopathological features in non-small-cell lung cancer patients. Diagn Pathol 10: 164, 2015.
8. Bai T, Dong DS and Pei L: Synergistic antitumor activity of resveratrol and miR-200c in human lung cancer. Oncol Rep 31: 2293-2297, 2014.
9. Shi L, Zhang S, Wu H, Zhang L, Dai X, Hu J, Xue J, Liu T, Liang Y and Wu G: MiR-200c increases the radiosensitivity of non-small-cell lung cancer cell line A549 by targeting VEGF-VEGFR2 pathway. PLoS One 8: e78344, 2013.
10. Li J, Li X, Ren S, Chen X, Zhang Y, Zhou F, Zhao M, Zhao C, Chen X, Cheng N, et al: miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type. Oncotarget 5: 7902-7916, 2014.
11. Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ, Wang YK, Zeng F, Zhou JH and Zhang YK: High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 29: 618-626, 2012.
12. Kim MK, Jung SB, Kim JS, Roh MS, Lee JH, Lee EH and Lee HW: Expression of microRNA miR-126 and miR-200c is associated with prognosis in patients with non-small cell lung cancer. Virchows Arch 465: 463-471, 2014.
13. Li X, Li D, Zhuang Y, Shi Q, Wei W and Ju X: Overexpression of miR-708 and its targets in the childhood common precursor B-cell ALL. Pediatr Blood Cancer 60: 2060-2067, 2013.
14. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
15. Hansen O, Schytte T, Nielsen M and Brink C: Age dependent prognosis in concurrent chemo-radiation of locally advanced NSCLC. Acta Oncol 54: 333-339, 2015.
16. Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo N and Aasebø U: Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: A subset analysis from a randomized clinical phase III trial. J Thorac Oncol 9: 825-833, 2014.
17. Liu CM, Peng CY, Liao YW, Lu MY, Tsai ML, Yeh JC, Yu CH and Yu CC: Sulforaphane targets cancer stemness and tumor initiating properties in oral squamous cell carcinomas via miR-200c induction. J Formos Med Assoc 116: 41-48, 2017.
18. Xie Y, Wehrkamp CJ, Li J, Wang Y, Wang Y, Mott JL and Oupický D: Delivery of miR-200c Mimic with Poly (amido amine) CXCR4 antagonists for combined inhibition of cholangiocarcinoma cell invasiveness. Mol Pharm 13: 1073-1080, 2016.
19. Zhang H, Liu J, Qu D, Wang L, Luo JY, Lau CW, Liu P, Gao Z, Tipoe GL, Lee HK, et al: Inhibition of miR-200c restores endothelial function in diabetic mice through suppression of COX-2. Diabetes 65: 1196-1207, 2016.
20. Mutlu M, Raza U, Saatci Ö, Eyüpoğlu E, Yurdusev E and Şahin Ö: MiR-200c: A versatile watchdog in cancer progression, EMT, and drug resistance. J Mol Med (Berl) 94: 629-644, 2016.
21. Dimri M, Kang M and Dimri GP: A miR-200c/141-BMI1 autoregulatory loop regulates oncogenic activity of BMI1 in cancer cells. Oncotarget 7: 36220-36234, 2016.
22. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M and Allgayer H: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 8: 1207-1216, 2010.
23. Tejero R, Navarro A, Campayo M, Viñolas N, Marrades RM, Cordeiro A, Ruíz-Martínez M, Santasusagna S, Molins L, Ramirez J and Monzó M: miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma. PLoS One 9: e101899, 2014.
24. Brücher BL and Jamall IS: Cell-cell communication in the tumor microenvironment, carcinogenesis, and anticancer treatment. Cell Physiol Biochem 34: 213-243, 2014.
25. Wang L, Li G, Yao ZQ, Moorman JP and Ning S: MicroRNA regulation of viral immunity, latency, and carcinogenesis of selected tumor viruses and HIV. Rev Med Virol 25: 320-341, 2015.
26. Bizzarri M and Cucina A: Tumor and the microenvironment: A chance to reframe the paradigm of carcinogenesis? Biomed Res Int 2014: 934038, 2014.
27. Liu S, Tetzlaff MT, Wang T, Yang R, Xie L, Zhang G, Krepler C, Xiao M, Beqiri M, Xu W, et al: miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment. Pigment Cell Melanoma Res 28: 431-441, 2015.
28. Tamagawa S, Beder LB, Hotomi M, Gunduz M, Yata K, Grenman R and Yamanaka N: Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma. Int J Mol Med 33: 879-886, 2014.
29. Rajabi H, Alam M, Takahashi H, Kharbanda A, Guha M, Ahmad R and Kufe D: MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition. Oncogene 33: 1680-1689, 2014.
30. Knezevic J, Pfefferle AD, Petrovic I, Greene SB, Perou CM and Rosen JM: Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential. Oncogene 34: 5997-6006, 2015.
31. Gravgaard KH, Lyng MB, Laenkholm AV, Søkilde R, Nielsen BS, Litman T and Ditzel HJ: The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. Breast Cancer Res Treat 134: 207-217, 2012.
32. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, et al: Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 17: 1101-1108, 2011.
33. Vilming Elgaaen B, Olstad OK, Haug KB, Brusletto B, Sandvik L, Staff AC, Gautvik KM and Davidson B: Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer 14: 80, 2014.
34. Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR and Goel A: Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg 259: 735-743, 2014.
35. Zhang HP, Sun FB and Li SJ: Serum miR-200c expression level as a prognostic biomarker for gastric cancer. Genet Mol Res 14: 15913-15920, 2015.
36. Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, Iglesias-Díaz P, Lorenzo-Patiño MJ, Haz M, Santamarina I, Blanco M, Fernández-Tajes J, Quindós M, et al: Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med 10: 186, 2012.
37. Antolin S, Calvo L, Blanco-Calvo M, Santiago MP, Lorenzo-Patiño MJ, Haz-Conde M, Santamarina I, Figueroa A, Antón-Aparicio LM and Valladares-Ayerbes M: Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. BMC Cancer 15: 297, 2015.